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ABSTRACT
Background Probody® therapeutics are antibody 
prodrugs that are activated in the tumor microenvironment 
by tumor- associated proteases, thereby restricting the 
activity to the tumor microenvironment and minimizing 
‘off- tumor’ toxicity. We report dose- escalation and single- 
agent expansion phase data from the first- in- human study 
of CX-072 (pacmilimab), a Probody checkpoint inhibitor 
directed against programmed death- ligand 1 (PD- L1).
Methods In the dose- escalation phase of this multicenter, 
open- label study (NCT03013491), adults with advanced 
solid tumors (naive to programmed- death-1/PD- L1 or 
cytotoxic T- lymphocyte- associated antigen 4 inhibitors) 
were enrolled into one of seven dose- escalation 
cohorts, with pacmilimab administered intravenously 
every 14 days. The primary endpoints were safety and 
determination of the maximum tolerated dose (MTD). In 
the expansion phase, patients with one of six prespecified 
malignancies (triple- negative breast cancer [TNBC]; anal 
squamous cell carcinoma [aSCC]; cutaneous SCC [cSCC]; 
undifferentiated pleomorphic sarcoma [UPS]; small bowel 
adenocarcinoma [SBA]; and thymic epithelial tumor [TET]); 
or high tumor mutational burden (hTMB) tumors were 
enrolled. The primary endpoint was objective response 
(Response Evaluation Criteria In Solid Tumors v.1.1).
Results An MTD was not reached with doses up to 30 mg/
kg. A recommended phase 2 dose (RP2D) of 10 mg/kg was 
chosen based on pharmacokinetic and pharmacodynamic 
findings in the expansion phase. Ninety- eight patients 
enrolled in the expansion phase: TNBC (n=14), aSCC 
(n=14), cSCC (n=14), UPS (n=20), SBA (n=14), TET (n=8), 
and hTMB tumors (n=14). Of 114 patients receiving 
pacmilimab at the RP2D, grade ≥3 treatment- related 
adverse events (TRAEs) were reported in 10 patients 
(9%), serious TRAEs in six patients (5%), and treatment 
discontinuation due to TRAEs in two patients (2%). Grade 
≥3 immune- related AEs occurred in two patients (rash, 
myocarditis). High PD- L1 expression (ie, >50% Tumor 
Proportion Score) was observed in 22/144 (19%) patients. 
Confirmed objective responses were observed in patients 
with cSCC (n=5, including one complete response), hTMB 
(n=4, including one complete response), aSCC (n=2), TNBC 
(n=1), UPS (n=1), and anaplastic thyroid cancer (n=1).
Conclusions Pacmilimab can be administered safely 
at the RP2D of 10 mg/kg every 14 days. At this dose, 
pacmilimab had a low rate of immune- mediated toxicity 
and showed signs of antitumor activity in patients not 
selected for high PD- L1 expression.
Trial registration number NCT03013491.
INTRODUCTION
The emergence of monoclonal antibodies 
directed against programmed- death-1 
(PD-1) and programmed- death ligand-1 
(PD- L1) has resulted in substantial clinical 
benefit, including improved overall survival 
in patients with an increasing range of 
solid tumors.1–6 Despite these considerable 
advances, dose- limiting—and occasionally 
fatal—immune- related adverse events (irAEs) 
reflecting non- tumor- specific immune system 
activation have been frequently reported. In 
a systematic review and meta- analysis of 13 
randomized controlled trials involving more 
than 6000 patients receiving anti- PD-1/PD- L1 
therapies, increased risk compared with stan-
dard therapies was reported for a range of 
irAEs, including hypothyroidism (odds ratio 
[OR]=6.92), pneumonitis (OR=5.37), colitis 
(OR=2.88), and hypophysitis (OR=3.88).7 
While not common, despite appropriate 
management, irAEs can lead to death.8 More-
over, irAEs often necessitate treatment inter-
ruptions or discontinuation and prolonged 
use of steroids, conceivably reducing 
anti- tumor efficacy.9 Therefore PD-1/
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PD- L1- targeted therapies with improved tolerability and 
safety are needed.
Probody® therapeutics are novel therapeutics designed 
to improve the safety and tolerability profile of mono-
clonal antibodies, antibody–drug conjugates, and other 
antibody- based therapies. These fully recombinant mono-
clonal antibody prodrugs comprise an active antibody (or 
antibody fragment) component, a masking peptide, and 
a protease- cleavable substrate linker peptide (figure 1). 
Exploiting the dysregulated protease activity in cancer 
cells, Probody therapeutics remain largely intact—and 
thus inactive—in the circulation, whereas in the tumor 
microenvironment, the masking peptide linker is cleaved 
by proteases allowing antibody binding to the target 
antigen expressed on the tumor.10–12
CX-072 (pacmilimab) is a Probody therapeutic directed 
against PD- L1. In preclinical studies, pacmilimab induced 
antitumor responses comparable to those of the same 
dose of the parental antibody in mice bearing MC38 
tumors.13 Pacmilimab accumulated in murine PD- L1- 
expressing tumors with minimal uptake in peripheral, 
non- cancerous lymphoid tissue, consistent with limited 
uptake in non- tumor PD- L1- expressing tissues and 
protection against autoimmunity.14 Data from transla-
tional studies evaluating on- treatment biopsies from 
patients with cancer showed that pacmilimab functioned 
as designed, with proteolytic activation of pacmilimab, 
expansion of intratumoral CD8+ T cells, and increased 
markers of T- cell activation, thereby demonstrating proof 
of mechanism.15
PROCLAIM- CX-072 (PRObody CLinical Assessment In 
Man, CX-072 Clinical Trial 001; NCT03013491), the first- 
in- human proof- of- concept study of pacmilimab, deter-
mined appropriate dosing and evaluated tolerability and 
preliminary antitumor efficacy of pacmilimab in patients 
with advanced, unresectable solid tumors. Here, we report 
safety and efficacy data of single- agent pacmilimab in a 
large, open- label, dose- finding proof- of- concept study in 
patients with selected advanced malignancies.
METHODS
Study design and participants
In this open- label study, immunotherapy- naive patients 
with advanced, unresectable solid tumors were recruited 
at 32 sites in the USA, The Netherlands, Poland, Spain, 
Ukraine, and UK. The study included three parallel 
cohorts that evaluated single- agent pacmilimab: dose- 
escalation cohorts to evaluate safety and to determine 
the maximum tolerated dose (MTD) and an expansion 
cohort to establish preliminary antitumor activity in 
selected malignancies.
Eligible patients were aged ≥18 years with Eastern 
Cooperative Oncology Group performance status 0 or 1, 
with an anticipated life expectancy of ≥3 months. Patients 
in the dose- escalation phase were required to have meta-
static or advanced unresectable solid tumors (measur-
able or non- measurable disease) for which no standard 
therapy was available and to be PD-1/PD- L1- and cytotoxic 
T- lymphocyte- associated antigen 4 (CTLA-4) inhibitor- 
naive. Patients with treated brain metastases were eligible 
if the brain metastases were stable and the patient did 
not require radiation therapy or steroids. Patients in 
the biomarker dose- escalation cohort were required to 
have tumors suitable for biopsy. To be enrolled into this 
group, patients were required to have tumors with PD- L1 
expression ≥1%, which was defined as Tumor Proportion 
Score (TPS) ≥1% membrane staining using the DAKO 
PD- L1 IHC 22C3 pharmDx assay (Agilent Technologies, 
Santa Clara, California, USA). PD- L1 expression was not 
required for enrollment in any other cohort.
Patients in the expansion phase were required to have 
measurable disease and to be PD-1/PD- L1- and CTLA-4 
inhibitor- naive. Patients with one of seven tumor types 
were eligible: (1) advanced or metastatic triple- negative 
breast cancer (TNBC) with documented progression 
after 1–3 systemic chemotherapy regimens for metastatic 
disease; (2) unresectable anal squamous cell carcinoma 
(aSCC) with prior radiation therapy and/or chemo-
therapy; (3) unresectable cutaneous SCC (cSCC); (4) 
undifferentiated pleomorphic sarcoma (UPS) with ≥1 
prior systemic therapy or unresectable, advanced disease 
with prior standard surgery and/or radiation therapy and 
TPS ≥1% membrane staining or unknown PD- L1 status; 
(5) small bowel adenocarcinoma (SBA) with 1–3 prior 
systemic chemotherapy regimens for metastatic or unre-
sectable disease; (6) thymic epithelial tumor (TET) with 
stage II–IV disease and ≥1 prior chemotherapy regimen; 
Figure 1 (A) Probody antibodies like pacmilimab comprise 
an anti- cancer antibody, a cleavable linker, and a masking 
peptide. (B) The Probody antibody enters the tumor 
microenvironment where tumor- associated proteases remove 
the masking peptide by cleaving the linker. (C) The unmasked 
antibody then selectively binds its target.
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or (7) patients whose tumors had high tumor mutational 
burden (hTMB), defined as ≥16 mutations/megabase 
in a recent sample using a validated assay and failure or 
refusal of standard therapy. These tumors were chosen 
based on a lack of available therapies to treat them at the 
time of study initiation and evidence in the medical liter-
ature of PD- L1 expression or preliminary responses to 
PD- (L)1- targeted therapies.
Exclusion criteria included prior chimeric antigen 
receptor T- cell therapy; prolonged QTc interval or use of 
medications known to cause QT prolongation; chemo-
therapy or immunotherapy within 2 weeks; prior or 
current autoimmune disease; history of a medical condi-
tion requiring >10 mg daily prednisone (or equivalent) 
or immunosuppressants; and unresolved grade >1 acute 
drug toxicity. Patients with TET who had a history of 
interstitial lung disease were excluded.
PD- L1 expression was determined on archived or 
biopsied tissue locally using the DAKO PD- L1 IHC 22C3 
pharmDx assay. TMB was determined locally using a Clin-
ical Laboratory Improvement Amendments validated 
assay from a recent tumor tissue or blood sample.
Procedures
In the dose- escalation phase, patients received single- 
agent pacmilimab (0.03, 0.1, 0.3, 1, 3, 10, and 30 mg/
kg) intravenously over 60 min (3–5 min for the 0.03 mg/
kg dose; 90 min for the 30 mg/kg dose) every 2 weeks. 
The dose- limiting toxicity (DLT) assessment period was 
28 days. Initially, one patient each was enrolled into the 
0.03, 0.1, and 0.3 mg/kg groups, and these patients were 
eligible for intra- patient dose escalation. Subsequent dose 
levels followed a 3+3 design. In the biomarker group, 
six additional patients with PD- L1–positive solid tumors 
received intravenous single- agent pacmilimab at doses 
of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg every 2 
weeks. Patients in the expansion phase received intrave-
nous pacmilimab at a dose of 10 mg/kg every 2 weeks, 
until confirmed disease progression or unacceptable 
toxicity.
Outcomes
AEs were assessed every 2 weeks and were graded 
using the National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events (v.4.03). Biopsies 
(if performed) occurred during the 28- day screening 
period and on study day 29. A DLT was defined as grade 
2 pneumonitis or ocular toxicity necessitating discontinu-
ation of pacmilimab, any grade 3 central nervous system 
event, treatment- related grade ≥3 AEs (except grade 4 
lymphopenia, non- febrile neutropenia, nausea, diarrhea, 
vomiting, asthenia, or constipation lasting ≤48 hours; 
correctable, asymptomatic electrolyte imbalances; clini-
cally manageable endocrinopathy; or tumor flare). irAEs 
were predefined as AEs with no clear alternate etiology 
that required systemic corticosteroid or immunosuppres-
sant treatment within 30 days of onset or that required 
the use of systemic hormonal supplementation (online 
supplemental table 1).
The primary efficacy endpoint was objective response 
rate (ORR) assessed by Response Evaluation Criteria In 
Solid Tumors (RECIST) v.1.1. Stable disease was defined 
according to RECIST v.1.1 and duration of at least 8 weeks 
was required to be included in the disease control rate. 
Duration of response (DOR), defined as the time from 
first documentation of objective response to first docu-
mented disease progression by RECIST v.1.1 or death from 
any cause, was a secondary efficacy endpoint. CT or MRI 
scans were performed every 8 weeks for 12 months and 
every 12 weeks thereafter until disease progression. Treat-
ment beyond the first instance of RECIST progressive 
disease was allowed according to the modified immune- 
related RECIST criteria.16 Patients with TNBC with skin 
lesions had cutaneous lesions photographed at all time 
points used for tumor assessment. After completing study 
treatment, patients were followed up every 3 months for 
survival (patients with progressive disease) or DOR.
Statistical analyses
To observe a sufficient number of objective responses 
in the dose- expansion phase with 95% probability, 20 
patients with UPS and 14 patients with each other cancer 
type were required. For most tumor types (aSCC, SBA, 
TET, TNBC, and hTMB), one patient with a confirmed 
objective response supported further study of single- 
agent pacmilimab in that tumor type. For UPS and cSCC, 
a confirmed objective response was required in two and 
three patients, respectively, for further study. Data from the 
dose- escalation phase were pooled by dose with data from 
patients who received ≤1 mg/kg combined into a single 
category. Data from the expansion phase were analyzed 
by tumor type; statistical summaries were descriptive. 
Data from the 16 patients in the dose- escalation 10 mg/kg 
group were included in the dose expansion analyses, for a 
total of 114 patients. Because patients with TET may be at 
high risk of irAEs,17–19 a separate post hoc safety analysis 
was conducted for these patients.
Safety data were summarized using the safety popula-
tion (all patients who received ≥1 dose of study drug). The 
efficacy population comprised all patients who received 
≥1 dose of study drug and who had measurable disease at 
baseline. Tumor response was analyzed per RECIST v.1.1, 
using exact two- sided 95% CI for all proportion estimates. 
Kaplan- Meier analyses were used to estimate DOR, with 
median duration and 95% CI based on the Brookmeyer 
and Crowley method.20
RESULTS
Patients were enrolled between January 19, 2017, and 
September 16, 2019; data are reported as of August 28, 
2020. In the dose- escalation phase, a total of 53 patients 
enrolled: ≤1 mg/kg (n=21), 3 mg/kg (n=13), 10 mg/
kg (n=16), and 30 mg/kg (n=3). Reasons for treat-
ment discontinuation in the dose- escalation phase were 
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symptomatic deterioration (defined as clinical signs of 
disease progression in the absence of confirmed radio-
graphic evidence; 29 [54.7%]), disease progression (13 
[24.5%]), treatment- related AEs (6 [11.3%]), inves-
tigator decision (2 [3.8%]), and patient decision (2 
[3.8%]). As of the cut- off date, one patient from this 
study phase remained on study on active treatment. A 
further 98 patients were enrolled in the expansion phase: 
14 patients with TNBC, 14 with aSCC, 14 with cSCC, 20 
with UPS, 14 with SBA, 8 with TET, and 14 with hTMB. 
Reasons for treatment discontinuation in these patients 
included symptomatic deterioration not confirmed as 
disease progression (46 [46.9%]), disease progression 
(28 [28.6%]), patient decision (7 [7.1%]), AE (2 [2.0%]), 
death due to disease progression (2 [2.0%]), pregnancy 
(1 [1.0%]), and discontinuing the parent study to enroll 
in the long- term extension study (1 [1.0%]). As of the 
cut- off date, 11 of these patients remained on study on 
active treatment.
Patient and disease characteristics are shown in table 1. 
Tumor types in the dose- escalation phase included 
TET (n=10); castration- resistant prostate cancer (n=4), 
cervical carcinoma (n=4), esophageal carcinoma (n=4), 
colon carcinoma (n=3), pancreatic carcinoma (n=3), 
uterine carcinoma (n=3), rectal carcinoma (n=3), aSCC 
(n=2), TNBC (n=2), ovarian carcinoma (n=2), uterine 
sarcoma (n=2), and other (n=11). In the dose- escalation 
phase (n=53), patients had received a median of two 
prior cancer regimens (range: 0–11). PD- L1 expression 
was high (defined as >50% TPS) in 23%, low (≥1% and 
≤50% TPS) in 28%, absent (<1% TPS) in 34%, and 
unknown in 15% of patients. In patients treated at the 
recommended phase 2 dose (n=114), PD- L1 expres-
sion was high in 19%, low in 31%, absent in 43%, and 
unknown in 7% of patients. The median number of prior 
regimens ranged from 0.5 (cSCC) to 4.5 (hTMB tumors) 
among tumor types, with the median number of prior 
regimens being two to three for most tumor types. PD- L1 
expression varied by tumor type, with the highest expres-
sion in TET (38% with high PD- L1 expression) and the 
lowest expression in TNBC and SBA (no expression in 
93% and 79%, respectively).
In the dose- escalation phase, the median duration of 
pacmilimab treatment was 2.3 months (range: 0.5–28.0 
months). Two patients experienced DLTs (one patient 
with grade 4 infusion- related reaction treated with 












































Sex, n (%)   
  Male 25 (47) 7 (44) 0 2 (14) 7 (50) 12 (60) 8 (57) 7 (88) 2 (14)
  Female 28 (53) 9 (56) 14 (100) 12 (86) 7 (50) 8 (40) 6 (43) 1 (13) 12 (86)
Race, n (%)   
  White 44 (83) 15 (94) 7 (50) 10 (71) 11 (79) 16 (80) 9 (64) 5 (63) 9 (64)
  Black 1 (2)   2 (14) 0 0 2 (10) 2 (14) 2 (25) 0
  Asian 1 (2)   0 0 0 1 (5) 0 1 (13) 0
  Unknown/other 7 (13) 1 (6) 5 (36) 4 (29) 3 (21) 1 (5) 3 (21) 0 5 (36)
ECOG PS, n (%)     
  0 23 (43) 10 (63) 6 (43) 9 (64) 6 (43) 1 (5) 6 (43) 3 (38) 5 (36)
  1 30 (57) 6 (38) 8 (57) 5 (36) 8 (57) 19 (95) 8 (57) 5 (63) 9 (64)





















PD- L1 expression status,* n (%)           
  High 12 (23) 5 (31) 0 3 (21) 4 (29) 4 (20) 0 3 (38) 3 (21)
  Low 15 (28) 4 (25) 1 (7) 9 (64) 6 (43) 6 (30) 3 (21) 3 (38) 3 (21)
  None 18 (34) 5 (31) 13 (93) 2 (14) 2 (14) 9 (45) 11 (79) 1 (13) 6 (43)
  Unknown 8 (15) 2 (13) 0 0 2 (14) 1 (5) 0 1 (13) 2 (14)
*Measured prospectively and defined by Tumor Proportion Score (TPS) using the DAKO PD- L1 IHC 22C3 pharmDx assay (Agilent Technologies, 
Santa Clara, California, USA). High expression was defined as TPS >50% membrane staining, low expression was defined as TPS ≥1% and ≤50% 
membrane staining, and no expression was defined as TPS <1%.
cSCC, cutaneous squamous cell carcinoma; hTMB, high tumor mutational burden; PD- L1, programmed death ligand-1; ECOG PS, Eastern 
Cooperative Oncology Group performance status; SBA, small bowel adenocarcinoma; SCC, squamous cell carcinoma; TET, thymic epithelial tumor; 
TNBC, triple- negative breast cancer; UPS, undifferentiated pleiomorphic sarcoma.
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Treatment- emergent AEs in ≥10% of patients (all severity grades)
  Fatigue 6 (29) 4 (31) 6 (38) 0 16 (30)
  Decreased appetite 8 (38) 3 (23) 4 (25) 0 15 (28)
  Nausea 5 (24) 5 (38) 4 (25) 0 14 (26)
  Cough 4 (19) 4 (31) 4 (25) 1 (33) 13 (25)
  Constipation 6 (29) 4 (31) 2 (13) 0 12 (23)
  Anemia 2 (10) 4 (31) 4 (25) 2 (67) 12 (23)
  Infusion- related reaction 5 (24) 3 (23) 3 (19) 0 11 (21)
  Back pain 3 (14) 3 (23) 3 (19) 1 (33) 10 (19)
  Dyspnea 1 (5) 4 (31) 4 (25) 0 9 (17)
  Arthralgia 2 (10) 2 (15) 2 (13) 2 (67) 8 (15)
  Fever 3 (14) 1 (8) 3 (19) 1 (33) 8 (15)
  Diarrhea 1 (5) 1 (8) 4 (25) 1 (33) 7 (13)
  Headache 3 (14) 1 (8) 3 (19) 0 7 (13)
  Increased blood alkaline 
phosphatase
2 (10) 0 3 (19) 1 (33) 6 (11)
  Dizziness 2 (10) 2 (15) 2 (13) 0 6 (11)
  Hyponatremia 3 (14) 1 (8) 2 (13) 0 6 (11)
  Pain in extremity 2 (10) 2 (15) 2 (13) 0 6 (11)
  Pruritus 3 (14) 0 2 (13) 1 (33) 6 (11)
Treatment- related AEs in ≥5% of patients (all severity grades)
  Patients with at least 1 10 (48) 8 (62) 11 (69) 3 (100) 32 (60)
  Infusion- related reaction 5 (24) 3 (23) 3 (19) 0 11 (21)
  Fatigue 3 (14) 1 (8) 4 (25) 0 8 (15)
  Arthralgia 0 1 (8) 2 (13) 2 (67) 5 (9)
  Myalgia 1 (5) 0 2 (13) 1 (33) 4 (8)
  Pruritus 2 (10) 0 1 (6) 0 3 (6)
  Fever 1 (5) 0 1 (6) 1 (33) 3 (6)
Immune- related AEs in ≥1 patient (all severity grades)
  Patients with at least 1 irAE 2 (10) 2 (15) 1 (6) 1 (33) 6 (11)
  Hypothyroidism 1 (5) 0 1 (6) 0 2 (4)
  Febrile neutropenia 0 1 (8) 0 0 1 (2)
  Thrombocytopenia 0 1 (8) 0 0 1 (2)
  Alanine aminotransferase 
increased
0 0 0 1 (33) 1 (2)
  Aspartate aminotransferase 
increased
0 0 0 1 (33) 1 (2)
  Pneumonitis 0 1 (8) 0 0 1 (2)
Serious AEs in >1 patient (all severity grades)
  Diarrhea 0 0 2 (13) 0 2 (4)
  Infusion- related reaction 1 (5) 0 1 (6) 0 2 (4)
  Lower respiratory tract infection 1 (5) 1 (8) 0 0 2 (4)
Grade 3–4 treatment- related AEs
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1 mg/kg; one patient with grade 3 febrile neutropenia 
treated with 3 mg/kg), but an MTD was not reached. 
In the absence of an MTD, the 10 mg/kg dose level was 
selected as the recommended phase 2 dose based on 
overall tolerability in addition to pharmacokinetic and 
pharmacodynamic considerations.21 The AE profile in 
the dose- escalation phase is summarized in table 2 and 
detailed in online supplemental tables 2 and 3. Grade 
3–4 treatment- related AEs were observed in eight patients 
(15%), with no AE occurring in more than one patient. 
All- grade irAEs occurred in six patients (11%). Three of 
these patients had grade 3–4 irAEs: febrile neutropenia 
and thrombocytopenia in one patient (3 mg/kg group), 
alanine aminotransferase increase and aspartate amino-
transferase increase in one patient (30 mg/kg group), 
and pneumonitis in one patient (3 mg/kg group). 
Serious AEs observed in >1 patient were diarrhea (10 mg/
kg; n=2, 1 was grade 2 and 1 was grade 3), infusion- related 
reaction (≤1 mg/kg and 10 mg/kg; n=2, 1 was grade 2 
and 1 was grade 4), and lower respiratory tract infection 
(≤1 mg/kg and 3 mg/kg; n=2, both were grade 3). In the 
dose- escalation phase, seven patients (13%) experienced 
AEs leading to treatment discontinuation; no AEs led to 
death.
Among all patients who received pacmilimab 10 mg/kg 
(n=114), the median duration of exposure was 3.0 months 
(range: 0.5–28.7 months). The safety profile is shown in 
table 3 and detailed in online supplemental tables 4 and 
5. Grade 3–4 treatment- related AEs were observed in 10 
(9%) patients: increased gamma glutamyl transferase 
(2%), increased lipase (2%), fatigue (1%), increased 
aspartate aminotransferase (1%), maculopapular rash 
(1%), enterocutaneous fistula (1%), hypertension (1%), 
and myocarditis (1%). All- grade irAEs occurred in 17 
patients (15%). Only two events were grade 3–4: macu-
lopapular rash (n=1) and myocarditis (n=1). Serious AEs 
were observed in 40 patients (35%); those observed in >1 
patient are listed in table 3. Grade 3–4 serious AEs occur-
ring in more than two patients were pneumonia (n=5, 
4%), pericardial effusion (n=3, 3%) and sepsis (n=3, 3%). 
Six serious AEs were considered related to pacmilimab, 
including two that were grade 3–4 serious AEs (grade 3 
myocarditis and grade 3 enterocutaneous fistula). Four 
patients (4%) had AEs leading to treatment discontin-
uation, and in two patients they were treatment- related 
(myocarditis and gamma- glutamyltransferase increased). 
No patients had AEs resulting in death.
Compared with other tumor types, patients with TET 
had a greater incidence of all- grade (70% vs 57%) and 
grade 3–4 treatment- related AEs (30% vs 9%). The inci-
dence of irAEs in the TET subgroup was similar to that in 
other tumor types (10% vs 15%).
Response data for patients treated with pacmilimab 
10 mg/kg are summarized in table 4. The overall ORR 
across tumor types was 12%. The highest ORRs were 
36% observed in patients with cSCC and 29% observed 
in patients with hTMB. The disease control rate in all 
patients treated at 10 mg/kg (defined as stable disease or 
better) was 42%. The disease control rates ranged from 
14% to 71%, depending on the tumor type. There were 
two complete responses, one in a patient with cSCC and 
one in a patient with an hTMB tumor (aSCC). One partial 
response was observed in the dose- escalation phase (n=53) 
in a patient with anaplastic thyroid cancer who received 
pacmilimab 10 mg/kg; no responses were observed in 
patients in the other dose- level groups. Among the 14 
patients with objective responses, 12 remained on study 
as of the data cut- off, and 10 patients had responses 
lasting more than 12 months. Pseudoprogression defined 
by disease response (irRECIST criteria) following the 
first instance of RECIST v.1.1 disease progression was 















Alanine aminotransferase increased 0 0 0 1 (33) 1 (2)
Anemia 0 1 (8) 0 0 1 (2)
Aspartate aminotransferase 
increased
0 0 0 1 (33) 1 (2)
Thrombocytopenia 0 1 (8) 0 0 1 (2)
Amylase increased 0 1 (8) 0 0 1 (2)
Epistaxis 0 0 1 (6) 0 1 (2)
Febrile neutropenia 0 1 (8) 0 0 1 (2)
ɣ-glutamyltransferase increased 0 0 1 (6) 0 1 (2)
Infusion- related reaction 1 (5) 0 0 0 1 (2)
Pneumonitis 0 1 (8) 0 0 1 (2)
Stress cardiomyopathy 1 (5) 0 0 0 1 (2)
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Treatment- emergent AEs in ≥10% of patients (all severity grades)
  Fatigue 6 (38) 4 (29) 3 (21) 7 (50) 5 (25) 6 (43) 3 (38) 4 (29) 38 (33)
  Diarrhea 4 (25) 3 (21) 1 (7) 6 (43) 6 (30) 4 (29) 1 (13) 5 (36) 30 (26)
  Anemia 4 (25) 1 (7) 4 (29) 3 (21) 7 (35) 3 (21) 3 (38) 3 (21) 28 (25)
  Decreased appetite 4 (25) 1 (7) 3 (21) 7 (50) 4 (20) 3 (21) 2 (25) 4 (29) 28 (25)
  Nausea 4 (25) 6 (43) 1 (7) 4 (29) 1 (5) 4 (29) 1 (13) 6 (43) 27 (24)
  AST increased 0 5 (36) 5 (36) 1 (7) 3 (15) 4 (29) 1 (13) 4 (29) 23 (20)
  Vomiting 3 (19) 2 (14) 2 (14) 3 (21) 3 (15) 3 (21) 1 (13) 5 (36) 22 (19)
  Cough 4 (25) 4 (29) 1 (7) 1 (7) 4 (20) 2 (14) 4 (50) 0 20 (18)
  Dyspnea 4 (25) 2 (14) 2 (14) 1 (7) 4 (20) 1 (7) 2 (25) 3 (21) 19 (17)
  Arthralgia 2 (13) 4 (29) 0 4 (29) 3 (15) 1 (7) 0 2 (14) 16 (14)
  Constipation 2 (13) 0 3 (21) 2 (14) 2 (10) 2 (14) 2 (25) 3 (21) 16 (14)
  ALT increased 1 (6) 1 (7) 3 (21) 1 (7) 3 (15) 3 (21) 1 (13) 2 (14) 15 (13)
  Fever 3 (19) 4 (29) 0 1 (7) 3 (15) 1 (7) 1 (13) 2 (14) 15 (13)
  Headache 3 (19) 3 (21) 0 2 (14) 4 (20) 0 0 2 (14) 14 (12)
  Back pain 3 (19) 3 (21) 2 (14) 2 (14) 1 (5) 0 1 (13) 2 (14) 14 (12)
  Rash 1 (6) 2 (14) 0 2 (14) 1 (5) 2 (14) 1 (13) 5 (36) 14 (12)
  Blood alkaline 
phosphatase increased
3 (19) 0 3 (21) 0 3 (15) 1 (7) 2 (25) 1 (7) 13 (11)
  Weight decreased 1 (6) 1 (7) 1 (7) 2 (14) 2 (10) 2 (14) 1 (13) 3 (21) 13 (11)
  Upper respiratory tract 
infection
2 (13) 1 (7) 1 (7) 1 (7) 1 (5) 1 (7) 3 (38) 2 (14) 12 (11)
  Urinary tract infection 1 (6) 2 (14) 1 (7) 1 (7) 2 (10) 2 (14) 0 2 (14) 11 (10)
Treatment- related AEs in ≥5% of patients (all severity grades)
  Patients with at least 1 11 (69) 10 (71) 8 (57) 9 (64) 5 (25) 5 (36) 6 (75) 12 (86) 66 (58)
  Fatigue 4 (25) 2 (14) 1 (7) 5 (36) 1 (5) 3 (21) 2 (25) 0 18 (16)
  AST increased 0 2 (14) 4 (29) 1 (7) 2 (10) 2 (14) 1 (13) 3 (21) 15 (13)
  ALT increased 0 1 (7) 3 (21) 1 (7) 2 (10) 2 (14) 1 (13) 2 (14) 12 (11)
  Infusion- related reaction 3 (19) 1 (7) 2 (14) 2 (14) 0 0 0 1 (7) 9 (8)
  Rash 1 (6) 1 (7) 0 1 (7) 1 (5) 1 (7) 0 4 (29) 9 (8)
  Arthralgia 2 (13) 2 (14) 0 1 (7) 0 1 (7) 0 2 (14) 8 (7)
  Decreased appetite 2 (13) 0 1 (7) 4 (29) 0 1 (7) 0 0 8 (7)
  Myalgia 2 (13) 1 (7) 0 0 1 (5) 1 (7) 0 2 (14) 7 (6)
  Diarrhea 0 1 (7) 0 2 (14) 1 (5) 0 0 2 (14) 6 (5)
  Vomiting 0 1 (7) 0 2 (14) 0 1 (7) 0 2 (14) 6 (5)
Immune- related AEs in ≥1 patient (all severity grades)
  Patients with at least 1 1 (6) 3 (21) 1 (7) 2 (14) 2 (10) 3 (21) 1 (13) 4 (29) 17 (15)
  AST increased 0 1 (7) 0 1 (7) 0 2 (14) 0 1 (7) 5 (4)
  Hypothyroidism 1 (6) 0 1 (7) 0 1 (5) 1 (7) 0 1 (7) 5 (4)
  ALT increased 0 0 0 1 (7) 0 2 (14) 0 1 (7) 4 (4)
  Rash 0 0 0 1 (7) 0 1 (7) 0 1 (7) 3 (3)
  Maculopapular rash 0 2 (14) 0 0 0 0 0 0 2 (2)
  Acute thyroiditis 0 0 0 0 1 (5) 0 0 0 1 (1)
  Arthralgia 0 1 (7) 0 0 0 0 0 0 1 (1)
  Hyperthyroidism 0 0 0 0 0 0 0 1 (7) 1 (1)
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at 10 mg/kg. One of these patients (rectal cancer) later 
achieved a disease response allowing the patient to 
undergo successful surgical resection of the tumor; the 
patient was disease- free at the time of data cut- off.
Changes in target lesions from baseline over time are 
shown in figure 2 by tumor type. Among responders, 
decreases in tumor size from baseline were observed 
in the first 8–16 weeks (figure 2B) and responses were 
durable (figure 2C).
DISCUSSION
This first- in- class, first- in- human study provides evidence 
of tolerability and clinical activity of single- agent 
pacmilimab in previously treated patients with advanced 
or metastatic solid tumors. In the dose- escalation phase, 
no MTD was reached. However, a recommended phase 
2 dose (10 mg/kg; n=114) was identified based on the 
tolerability profile on chronic administration as reported 
here, and pharmacokinetic considerations reported 
separately.21 Specifically, pacmilimab 10 mg/kg had an 
estimated half- life of approximately 12 days, and pharma-
cokinetic simulations suggested that following adminis-
tration every 2 weeks >95% of patients would be expected 
to maintain pacmilimab trough levels above the targeted 
level.21
Among patients treated at the recommended phase 2 
dose (n=114), the discontinuation rate due to treatment- 
related AEs was 2%. Preliminary pharmacokinetic data 
suggest that pacmilimab circulates predominantly (ie, 






















Grade 3–4 treatment- related AEs in >1 patient
  Patients with at least 1 2 (13) 2 (14) 0 0 0 2 (14) 3 (38) 1 (7) 10 (9)
  ɣ-glutamyltransferase 
increased
1 (6) 1 (7) 0 0 0 0 0 0 2 (2)
  Lipase increased 0 0 0 0 0 0 2 (25) 0 2 (2)
  AST increased 0 0 0 0 0 0 0 1 (7) 1 (1)
  Enterocutaneous fistula 1 (6) 0 0 0 0 0 0 0 1 (1)
  Fatigue 0 0 0 0 0 1 (7) 0 0 1 (1)
  Hypertension 0 0 0 0 0 1 (7) 0 0 1 (1)
  Maculopapular rash 0 1 (7) 0 0 0 0 0 0 1 (1)
  Myocarditis 0 0 0 0 0 0 1 (13) 0 1 (1)
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cSCC, cutaneous squamous cell carcinoma; hTMB, high tumor 
mutational burden; SBA, small bowel adenocarcinoma; SCC, squamous cell carcinoma; TET, thymic epithelial tumor; TNBC, triple- negative breast 
cancer; UPS, undifferentiated pleiomorphic sarcoma.
Table 3 Continued
Table 4 Best tumor response per RECIST v.1.1 in evaluable patients* who had at least one post- baseline disease assessment 






































  Complete response, n (%) 0 0 0 1 (7) 0 0 0 1 (7) 2 (2)
  Partial response, n (%) 1 (8) 1 (7) 2 (13) 4 (29) 1 (5) 0 0 3 (21) 12 (11)
Stable disease, n (%) 3 (25) 7 (47) 6 (40) 5 (36) 4 (20) 2 (14) 5 (50) 2 (14) 34 (30)
Disease control rate‡, n (%) 4 (33) 8 (53) 8 (53) 10 (71) 5 (25) 2 (14) 5 (50) 6 (43) 48 (42)
Progressive disease, n (%) 7 (58) 5 (33) 7 (47) 4 (29) 12 (60) 9 (64) 4 (40) 5 (36) 53 (47)
Discontinued early§, n (%) 1 (8) 2 (13) 0 0 3 (15) 3 (21) 1 (10) 3 (21) 13 (11)
*Treated patients who had an adequate baseline assessment.
†ORR is the sum of the confirmed partial and complete responses.
‡Disease control rates is the sum of the complete responses, partial responses, and stable disease.
§Patients who discontinued the study without a post- baseline tumor assessment.
cSCC, cutaneous squamous cell carcinoma; hTMB, high tumor mutational burden; ORR, objective response rate; RECIST, Response Evaluation 
Criteria in Solid Tumors; SBA, small bowel adenocarcinoma; SCC, squamous cell carcinoma; TET, thymic epithelial tumor; TNBC, triple- negative 
breast cancer; UPS, undifferentiated pleiomorphic sarcoma.
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of clearance via peripheral targets (ie, target- mediated 
drug disposition).21 Taken together, these data suggest 
that Probody technology functioned as expected, with 
limited peripheral activation of the checkpoint inhibitor.
Anti- PD-1/PD- L1 therapies are potentially limited by 
the development of irAEs. The incidence of all- grade 
irAES varies among PD-1 and PD- L1 inhibitor thera-
pies but have occurred in as many as 30% of patients in 
phase 3 trials.22 The incidence of severe irAEs requiring 
medical intervention or hold/discontinuation of immu-
notherapy is estimated to range from 0.5% to 13% of 
patients receiving monotherapy.23 The most common 
irAEs among patients receiving anti- PD-1/PD- L1 agents 
include hypothyroidism (5.6%), pneumonitis (2.2%), 
colitis (0.7%), and hypophysitis (0.3%).7 Although rare, 
fatal irAEs can occur with PD-1 (0.36%) and PD- L1 
(0.38%) inhibitors,8 with pneumonitis and cardiac irAEs 
being the most common causes of death.
In the present study—the first of pacmilimab—rela-
tively common irAEs, such as pneumonitis and colitis, 
were seen only once (pneumonitis) or not at all (colitis) 
in the 151 patients treated with single- agent pacmilimab, 
suggesting a low incidence of these important AEs. 
However, it must be noted that this is an early- phase 
study and is therefore limited by the number of patients 
exposed to pacmilimab, a heterogeneous patient popu-
lation, and patients who discontinued treatment due to 
early disease progression.
Data from the 114 patients treated in this study with 
pacmilimab at 10 mg/kg suggest preliminary antitumor 
activity, with an ORR of 12% and a disease control rate of 
42%. The prespecified efficacy criteria to justify further 
exploration of single- agent pacmilimab were met for 
TNBC, aSCC, cSCC, and hTMB. At the time of trial initia-
tion, no PD(L)-1 inhibitor was approved for these cancer 
types, although responses to checkpoint inhibitor therapy 
had been documented in these tumor types.24–27 Of note, 
patients were not selected for PD- L1 expression; among 
patients treated with 10 mg/kg pacmilimab who had 
available PD- L1 expression data, 49 of 106 (46%) had no 
PD- L1 expression, and 35 of 106 (33%) had low expres-
sion. There was no clear relationship between response to 
treatment and high PD- L1 expression (figure 2A).
The clinical activity observed with pacmilimab 10 mg/
kg compares favorably to historical data with other PD- L1 
or PD-1 inhibitors in patient populations unselected for 
PD- L1 expression.28 Although none of the TNBC patients 
in our study had high PD- L1 expression, the ORR was 7%, 
Figure 2 (A) Best percentage change in target lesion size by tumor type during the expansion phase. (B) Change in target 
lesion burden over time by tumor type during the expansion phase. (C) Duration of response. *Indicates that the patient is still 
on treatment. #Indicates tumor with high (ie, >50% tumor proportion score) PD- L1 expression
Note: One patient with a high mutational burden tumor and one patient with cutaneous squamous cell carcinoma had a 
confirmed complete response. Some of the target lesions were lymph nodes, accounting for reduction in target lesion 
values from baseline of less than 100%. One patient with undifferentiated pleomorphic sarcoma and a confirmed partial 
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which is similar to that observed with single- agent atezoli-
zumab in patients with metastatic TNBC in the second- line 
setting and beyond (n=94; 6%). 29 The response rate with 
pacmilimab in patients with aSCC (13%) is similar to that 
observed with single- agent pembrolizumab in patients 
with recurrent, PD- L1- positive aSCC (n=24; 17%).26 
Although meaningful comparisons between studies are 
confounded by differences in design, patient characteris-
tics, and the non- randomized nature of the comparison, 
the results observed with pacmilimab suggest potentially 
meaningful clinical activity.
Collectively, these data suggest that pacmilimab has a 
favorable tolerability profile with limited off- tumor toxicity. 
The potential for improved safety and tolerability of 
Probody therapeutics compared with conventional check-
point inhibitors may yield optimal dose intensity with fewer 
dose interruptions or treatment discontinuations and may 
also allow improved tolerability of checkpoint inhibitor 
combinations with other checkpoint inhibitors, tyrosine 
kinase inhibitors, or cytotoxic chemotherapy. These prelim-
inary findings with pacmilimab in patients with pretreated 
advanced solid tumors are encouraging and support further 
clinical evaluation. The tolerability and clinical activity of 
pacmilimab in combination with ipilimumab within the 
current study is reported separately30 .
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